The "omics" — genomics, transcriptomics, metabolomics and proteomics — are booming in biotech, with more big raises expected in 2023.
Health, Wellness & Biotech
This year hasn’t exactly been a blockbuster for the IPO markets. Venture funding has tanked and fewer startups have dared to step into the public...
We looked at 2021's six largest pre-IPO round recipients and how they’ve fared since going public. To put it mildly, most underperformed expectations...
We here at Crunchbase love to talk about billions — billions in valuations, billions in revenue and billions in fundraising, even in a volatile year...
A lot happened in tech in 2022, much of it not particularly good. Bradley Tusk, co-founder and managing partner at Tusk Venture Partners, tackles the...
The sharp downturn in startup funding between 2021 and 2022 extends to venture-backed companies working on cancer therapies and diagnostics.
It was a weird week. Two of the top four rounds were actually large down rounds and a third came with “restructuring” and layoff news. Not exactly...
As we revisit a previously curated list of truly terrible SPAC performers, it’s clear they’re closing out the year at a particularly low point.
MasterControl, a decades old Salt Lake City-based company that provides software to manage the development of life science products, reached unicorn...
HistoSonics raised $85 million in funding led by Johnson & Johnson for a futuristic device it says could demolish tumors in patients with liver...
The current state of flux gives us the rare opportunity to build on telehealth successes.
67.1K Followers